TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06107231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Honey
Description: Honey representing 7% of total energy (kilocalorie) needs (40-70 grams)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Honey
Description: Honey representing 7% of total energy (kilocalorie) needs (40-70 grams)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Sucrose representing 7% of total energy (kilocalorie) needs (40-70 grams)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Sucrose representing 7% of total energy (kilocalorie) needs (40-70 grams)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Honey plus almonds
Description: Honey representing 7% of total energy (kilocalorie) needs (40-70 grams) plus 1 ounce almonds (28 grams)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Honey plus almonds
Description: Honey representing 7% of total energy (kilocalorie) needs (40-70 grams) plus 1 ounce almonds (28 grams)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose plus almonds
Description: Sucrose representing 7% of total energy (kilocalorie) needs (40-70 grams) plus 1 ounce almonds (28 grams)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose plus almonds
Description: Sucrose representing 7% of total energy (kilocalorie) needs (40-70 grams) plus 1 ounce almonds (28 grams)
Study: NCT05497245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobile app-based breastfeeding education
Description: The main screen of the application used to be six screens. These six screens; Breastfeeding, Expressing, Contingencies, Frequently asked questions and my Breastfeeding Log and Breastfeeding diary. Mothers could record the number and duration of breastfeeding, milking status, the baby's height and weight, if it was a measure, the breastfeeding problem and solutions they encountered, on the Breastfeeding Introduction tab, and they could follow their breastfeeding status in the Breastfeeding Diary tab.
Study: NCT04808011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent Dialysis Assistant (IDA)
Description: The IDA is intended for home dialysis for subjects who are stage 5 kidney diease patients and who perform Peritoneal Dialysis. The system is used deveral times a day for approximately 20 minutes for each cycle. During the interventional period, subjects will use only the investigational IDA system for their in/out exchanges.
Study: NCT06304012

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric tube feeding
Description: The patients in the control group were provided nutrition support with Nasogastric tube feeding, while the feeding process strictly followed the relevant guideline. During the treatment, the patients remained in a continuous state of tube indwelling, receiving feeding every 2-3 hours with a maximum feeding volume of 200ml, of which the contents were consistent with the observation group. The entire feeding process was conducted by trained nursing staff. Besides, the tube was replaced by a new one every 5-7 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Oro-esophageal Tube Feeding
Description: The entire feeding process strictly followed the standard procedure of Intermittent Oro-esophageal Tube Feeding(18). During the feeding process, patients were maintained in a semi-recumbent position with their head elevated, facilitating the placement of the tube into the oral cavity along one side, with the chin brought close to the manubrium sterni.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~Others: Regular turning, back patting, and position changes performed by caregivers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation therapy
Description: Acupuncture: Regular acupuncture treatment that can prevent muscle atrophy, improve circulation, and have a stimulating effect.~Exercise therapy: Training that focused on limb movements or joint mobilization to prevent muscle contracture, reduce joint mobility, improve spasms, and promote blood circulation.~Others: Regular turning, back patting, and position changes performed by caregivers.
Study: NCT05525208

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 subunit protein recombinant vaccine
Description: SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 subunit protein recombinant vaccine
Description: SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 subunit protein recombinant vaccine
Description: SARS-CoV-2 RBD subunit recombinant protein, manufactured by PT. Bio Farma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Active Comparator
Description: The Pfizer-BioNTech® COVID-19 vaccine or BNT162b2, is an mRNA vaccine encoding a P2 mutant spike protein (PS 2) and formulated as an RNA-lipid nanoparticle of nucleoside-modified mRNA (modRNA).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Active Comparator
Description: The Pfizer-BioNTech® COVID-19 vaccine or BNT162b2, is an mRNA vaccine encoding a P2 mutant spike protein (PS 2) and formulated as an RNA-lipid nanoparticle of nucleoside-modified mRNA (modRNA).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Active Comparator
Description: The Pfizer-BioNTech® COVID-19 vaccine or BNT162b2, is an mRNA vaccine encoding a P2 mutant spike protein (PS 2) and formulated as an RNA-lipid nanoparticle of nucleoside-modified mRNA (modRNA).
Study: NCT05981729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technology enriched stroke rehabilitation
Description: In order to increase time spent in rehabilitation activity, participants will be prescribed and supported to use (by NHS staff) commercially available technology, such as robotics, adapted treadmills, virtual reality, and mobile digital devices such as smartphones, tablets, and wearable sensors.
Study: NCT06268210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib+Pemetrexed+Carboplatin
Description: Lazertinib: 240 mg once daily (pre-/post-surgery for 3 years) Pemetrexed: 500 mg/m2 every 3 weeks (neoadjuvant therapy for 3 cycles) Carboplatin: AUC5 every 3 weeks (neoadjuvant therapy for 3 cycles)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lazertinib
Description: Lazertinib will be administered at a dosage of 240 mg once daily, both before and after surgery, for a duration of 3 years.
Study: NCT04524104

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lumen Treatment
Description: the virtual AI agent, Lumen, via an iPad-based application. Each participant will receive a locked, encrypted study iPad installed with Lumen. They will complete 8 problem solving therapy (PST) sessions beginning with 4 weekly and then 4 biweekly intervals over 12 weeks on their assigned iPad.
Study: NCT04841044

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cetoleic acid
Description: Very long monounsaturated fatty acid ( C22:1n-11)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Oil
Description: Control oil consisting of: mix of anchovy oil, olive oil, high-oleic sunflower oil and rapeseed oil
Study: NCT04880343

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group (A)
Description: Group that will take a daily dose of the commercial dietary supplement provided by the sponsor, composed of mannose, cran-max and vitamin D for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group (B)
Description: Group that will take a daily dose of the commercial dietary supplement provided by the sponsor, composed of mannose, cran-max and vitamin D for 3 months
Study: NCT05407363

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ABB and ATG with simultaneous implant placement
Description: Ridge augmentation using ABB and ATG as a graft material with simultaneous implant placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: XBB and ATG with simultaneous implant placement
Description: Ridge augmentation using XBB and ATG as a graft material with simultaneous implant placement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ABB and ABG with simultaneous implant placement
Description: Ridge augmentation using ABB and ABG as a graft material with simultaneous implant placement
Study: NCT05638230

Intervention type: DIAGNOSTIC_TEST
Intervention: Left atrial reservoir strain
Description: LA strain measurements can be obtained by two dimensional (2D) speckle tracking echocardiography (STE). Longitudinal strain and strain rate curves are generated for each of six atrial segments, obtained from the apical four and two chamber views.~In the reservoir phase, as the LA fills and stretches, there is positive atrial strain that reaches its peak in systole at the end of LA filling, prior to opening of the mitral valve. Following this, passive LA emptying ensues with opening of the mitral valve resulting in decreased atrial strain with negative deflection of the strain curve up to a plateau period which is analogous to diastasis. LA reservoir strain (LARS), or peak atrial longitudinal strain or LA systolic strain, is measured at the end of the reservoir phase.

Intervention type: DIAGNOSTIC_TEST
Intervention: Left atrial reservoir strain
Description: LA strain measurements can be obtained by two dimensional (2D) speckle tracking echocardiography (STE). Longitudinal strain and strain rate curves are generated for each of six atrial segments, obtained from the apical four and two chamber views.~In the reservoir phase, as the LA fills and stretches, there is positive atrial strain that reaches its peak in systole at the end of LA filling, prior to opening of the mitral valve. Following this, passive LA emptying ensues with opening of the mitral valve resulting in decreased atrial strain with negative deflection of the strain curve up to a plateau period which is analogous to diastasis. LA reservoir strain (LARS), or peak atrial longitudinal strain or LA systolic strain, is measured at the end of the reservoir phase.
Study: NCT05284097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo
Description: Ad26.ZEBOV - is an adenovirus serotype 26 vector expressing the glycoprotein (GP) of the Ebola virus (EBOV) Mayinga variant~MVA-BN-Filo - is a Modified Vaccinia Ankara (MVA) - Bavarian Nordic (BN) vector expressing the GPs of EBOV, Sudan virus (SUDV) and Marburg virus (MARV) and the nucleoprotein of Tai Forest virus
Study: NCT05791721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib 90 Mg Oral Tablet
Description: Intervention will be applied one hour before surgical extraction of impacted mandibular third molar

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4mg
Description: Intervention will be applied one hour before surgical extraction of impacted mandibular third molar
Study: NCT05124899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP UnScented
Description: Sunscreen lip balm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP Herbal Mint
Description: Sunscreen lip balm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAP Mountain Berry
Description: Sunscreen lip balm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPF Standard Sunscreen
Description: SPF Standard (7 percent \[%\] Padimate-O and 3% Oxybenzone)
Study: NCT04570085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: 100mg caffeine capsule treatment, beginning after caffeine diet during 6 weeks, titrate in 3 weeks (by 100mg stages) until 400mg aim dose per day in 2 doses during 27 weeks, and finally interrupt according to the same negative titration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule treatment, beginning after caffeine diet during 6 weeks, titrate in 3 weeks until 2 doses aim dose per day during 27 weeks, and finally interrupt according to the same negative titration.
Study: NCT05101109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL501
Description: ABL501 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in the dose-expansion part will be re-evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
Study: NCT04438551

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dietary counseling
Description: Subjects will be given a low sodium diet handout with counseling, complete a validated questionnaire on low sodium foods, and complete a 24-hr urine collection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard dietary counseling
Description: Subjects will be given a low sodium diet handout with counseling, complete a validated questionnaire on low sodium foods, and complete a 24-hr urine collection.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile app
Description: Subjects will be given a low sodium diet handout with counseling, complete a validated questionnaire on low sodium foods, and complete a 24-hr urine collection. Subjects will be given a mobile app to build grocery lists where the sodium level will be recorded and tracked in the app.
Study: NCT05261191

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGD020
Description: MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGD020
Description: MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGD020
Description: MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGD020
Description: MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGD020
Description: MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGD020
Description: MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGD020
Description: MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGD020
Description: MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGD020
Description: MGD020 is a bispecific DART molecule that binds CD3 and gp41 subunit of HIV-1 envelope.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGD014
Description: MGD014 is a bispecific DART molecule that binds CD3 and gp120 subunit of HIV-1 envelope.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGD014
Description: MGD014 is a bispecific DART molecule that binds CD3 and gp120 subunit of HIV-1 envelope.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGD014
Description: MGD014 is a bispecific DART molecule that binds CD3 and gp120 subunit of HIV-1 envelope.
Study: NCT06632860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-TATE-RGD
Description: Intravenous injection of 68Ga-TATE-RGD with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses will be used to image lesions of by dual-targeted postive cancers PET/CT.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18-FDG
Description: Intravenous injection of 18F-FDG with the dosage of 1.8-2.2 MBq(0.12-0.15mCi/kg). Tracer doses will be used to lesions therapy of dual-targeted postive cancers by SPECT/CT.
Study: NCT05968521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR): Experimental
Description: CR will consist of six sessions lasting 90 minutes of a structured exercise programme, educational and lifestyle modules, and a psychological component. Sessions include group discussions, experiential learning and homework tasks that participants are asked to complete between sessions. Participants in this treatment arm will also receive routine clinical outpatient management alongside CR.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual: Control
Description: Treatment as usual will include routine clinical outpatient management.
Study: NCT05196529

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: All participants will undergo inspiratory muscle training.
Study: NCT04186169

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Catheter ablation
Description: Catheter ablation
Study: NCT05875545

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Breathing Exercises
Description: Diaphragmatic breathing exercises with a physiotherapist for 8 weeks, two days a week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Exercises
Description: Pelvic floor exercises with a physiotherapist for 8 weeks, two days a week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Exercises
Description: Pelvic floor exercises with a physiotherapist for 8 weeks, two days a week
Study: NCT06423989

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: IVIG
Description: treatment of subfertility
Study: NCT06004687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen mannitol
Description: Intravenous acetaminophen was administered 30 minutes before anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Intravenous acetaminophen was administered 30 minutes before anesthesia
Study: NCT04186169

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Catheter ablation
Description: Catheter ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Catheter ablation
Study: NCT06478719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB-1603
Description: FB-1603 (165 mg/cap) oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB-1603
Description: FB-1603 (165 mg/cap) oral capsule
Study: NCT05539404

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular treatment in addition of best medical treatment.
Description: Endovascular treatment (EVT) of acute ischemic stroke (AIS) related to an anterior large cerebral vessel occlusion (LVO)
Study: NCT04917692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 2.5 mg daily
Study: NCT05102903

Intervention type: DRUG
Group type: OTHER
Intervention: BR1016A
Description: All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.

Intervention type: DRUG
Group type: OTHER
Intervention: BR1016A
Description: All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.

Intervention type: DRUG
Group type: OTHER
Intervention: BR1016B
Description: All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.

Intervention type: DRUG
Group type: OTHER
Intervention: BR1016B
Description: All subjects who have been fasting for at least 10 hours prior to administration will take 1 tablet of study drug or comparator orally with 150 mL of water at room temperature at around 8 a.m. on the administration day of each period.
Study: NCT05420662

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manipulation of vagina during abdominal hysterectomy operation
Description: The manipulator applied vaginally prevents unnecessary vaginal length loss by ensuring that the vaginal cuff is cut from the top point.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classical conventional abdominal hysterectomy operation
Description: Classical conventional abdominal hysterectomy operation without any manipulation from the vagina.
Study: NCT05540080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899
Description: Treatment with applicators C4/C5 to the BTL-899 system.
Study: NCT05507008

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kenetik Ketone Drink
Description: BHB supplementation
Study: NCT05886647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active non-invasive stimulation and inspiratory muscle training
Description: Simultaneously with the current application, the patient will perform inspiratory muscle training (IMT) by KH2; PowerBreathe International Ltd. UK along with a feedback Breathelink, consisting of three series of two minutes of maximum and deep inspirations followed by two minutes of rest between them, totaling six minutes of TMI.
Study: NCT04582487

Intervention type: OTHER
Group type: OTHER
Intervention: bone marrow and/or peripheral blood samples withdrawal
Description: bone marrow and/or peripheral blood samples evaluation
Study: NCT05715801

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen therapy
Description: The hyperbaric oxygen group was given 60 minutes of pure oxygen under 2ATA (Atmosphere Absolute, ATA) and 5 minutes of rest in between.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional oxygen therapy
Description: Conventional oxygen therapy group breathed 27% oxygen at 1.03 ATA for 60 minutes. (The chamber pressure was increased to 1.2ATA with circulating air noise for the first 5 minutes of the experiment, then reduced to 1.03 ATA for the next 5 minutes.)